Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 10/20 | 0.48 |
| ▸ | CHEK1 | O14757 | 5/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.32 |
| ▸ | APP | P05067 | 1/20 | 0.32 |
| ▸ | BACE1 | P56817 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3548090 | 1.00 | OPRL1 (0.48) | OPRL1CHEK1KCNH2OPRK1APP | |
| SCHEMBL3543411 | 0.90 | OPRL1 (0.48) | OPRL1KCNH2CYP2D6GRIN2B | |
| SCHEMBL3541528 | 0.87 | OPRL1 (0.46) | OPRL1CHEK1 | |
| SCHEMBL3540425 | 0.86 | OPRL1 (0.66) | OPRL1CHEK1KCNH2OPRK1 | |
| SCHEMBL3538955 | 0.80 | OPRL1 (0.43) | OPRL1KCNH2 | |
| SCHEMBL3549840 | 0.77 | OPRL1 (0.54) | OPRL1KCNH2OPRK1 | |
| SCHEMBL3540330 | 0.72 | OPRL1 (0.53) | OPRL1CHEK1KCNH2OPRK1 | |
| SCHEMBL3540333 | 0.72 | OPRL1 (0.53) | OPRL1CHEK1KCNH2OPRK1 | |
| SCHEMBL3541395 | 0.70 | OPRL1 (0.71) | OPRL1KCNH2OPRK1 | |
| SCHEMBL3541398 | 0.70 | OPRL1 (0.71) | OPRL1KCNH2OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7829586-B2 | Aryl-substituted nitrogen-containing heterocyclic compounds | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-11-09 | — | — | US | disclosed |
| US-20090275617-A1 | Aryl-Substituted Nitrogen-Containing Heterocyclic Compounds | MSD K.K. (JP) | 2009-11-05 | — | — | US | disclosed |
| EP-1935881-A1 | ARYL-SUBSTITUTED NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-06-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275617-A1 | Aryl-Substituted Nitrogen-Containing Heterocyclic Compounds | OPRL1, NPSR1, NPBWR1 | OPRL1 1/4885CHEK1 3856/4885KCNH2 766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.